NASDAQ:BCLIBrainstorm Cell Therapeutics Stock Price, Forecast & News

Brainstorm Cell Therapeutics' stock was trading at $6.68 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BCLI stock has increased by 35.9% and is now trading at $9.08. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Brainstorm Cell Therapeutics.

Brainstorm Cell Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Brainstorm Cell Therapeutics.

Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) issued its earnings results on Thursday, May, 7th. The biotechnology company reported ($0.32) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.09. View Brainstorm Cell Therapeutics' earnings history.

1 brokers have issued 1-year price objectives for Brainstorm Cell Therapeutics' shares. Their forecasts range from $9.00 to $9.00. On average, they expect Brainstorm Cell Therapeutics' stock price to reach $9.00 in the next twelve months. This suggests that the stock has a possible downside of 0.9%. View analysts' price targets for Brainstorm Cell Therapeutics.

News articles about BCLI stock have trended somewhat positive on Saturday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Brainstorm Cell Therapeutics earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news aboutBrainstorm Cell Therapeutics.

Brainstorm Cell Therapeutics saw a increase in short interest in April. As of April 30th, there was short interest totaling 2,290,000 shares, an increase of 22.5% from the April 15th total of 1,870,000 shares. Based on an average daily trading volume, of 754,300 shares, the days-to-cover ratio is currently 3.0 days. Approximately 10.8% of the company's shares are sold short. View Brainstorm Cell Therapeutics' Current Options Chain.

Some companies that are related to Brainstorm Cell Therapeutics include Translate Bio (TBIO), BAVARIAN NORDIC/S (BVNRY), Orchard Therapeutics (ORTX), Replimune Group (REPL), Krystal Biotech (KRYS), Sorrento Therapeutics (SRNE), Avrobio (AVRO), BioCryst Pharmaceuticals (BCRX), AVITA MED LTD/S (RCEL), Cellectis (CLLS), Aerie Pharmaceuticals (AERI), Vericel (VCEL), Osiris Therapeutics (OSIR), Oyster Point Pharma (OYST) and AVITA MED LTD/S (AVMXY). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Brainstorm Cell Therapeutics investors own include Organovo (ONVO), Gene Biotherapeutics (CRXM), Protalix Biotherapeutics (PLX), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), IsoRay (ISR), Mellanox Technologies (MLNX), Caladrius Biosciences (CLBS), Abeona Therapeutics (ABEO) and Adaptimmune Therapeutics (ADAP).

Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."

Brainstorm Cell Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.46%), Raymond James & Associates (0.77%), Geode Capital Management LLC (0.58%), EAM Investors LLC (0.44%), Phoenix Holdings Ltd. (0.40%) and WINTON GROUP Ltd (0.26%). Company insiders that own Brainstorm Cell Therapeutics stock include Irit Arbel, June Sherie Almenoff, Preetam Shah and Ralph Dr Kern. View institutional ownership trends for Brainstorm Cell Therapeutics.

BCLI stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., EAM Investors LLC, Phoenix Holdings Ltd., Raymond James & Associates, JPMorgan Chase & Co., Abner Herrman & Brock LLC, Geode Capital Management LLC, and Steward Partners Investment Advisory LLC. Company insiders that have bought Brainstorm Cell Therapeutics stock in the last two years include June Sherie Almenoff, Preetam Shah, and Ralph Dr Kern. View insider buying and selling activity for Brainstorm Cell Therapeutics.

Shares of BCLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BCLI stock can currently be purchased for approximately $9.08.

Brainstorm Cell Therapeutics has a market capitalization of $267.32 million. The biotechnology company earns $-23,250,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. Brainstorm Cell Therapeutics employs 31 workers across the globe.

The official website for Brainstorm Cell Therapeutics is www.brainstorm-cell.com.

Brainstorm Cell Therapeutics' mailing address is 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 201-488-0460 or via email at [email protected]